Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
The Journal of Clinical Psychiatry|April 21, 2004
Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepamGlenn W Currier, James C-Y Chou, David Feifel, et al.Headache|May 6, 2015
AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacksStewart J Tepper, Roger K Cady, Stephen Silberstein, et al.The Journal of Clinical Psychiatry|September 13, 2006
A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorderGeorge M Simpson, Ramy A Mahmoud, Robert A Lasser, et al.Annals of Internal Medicine|November 3, 2007
Risperidone for treatment-refractory major depressive disorder: a randomized trialRamy A Mahmoud, Gahan J Pandina, Ibrahim Turkoz, et al.Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 17, 2018
Low-dose intranasal oxytocin delivered with Breath Powered device modulates pupil diameter and amygdala activity: a randomized controlled pupillometry and fMRI studyDaniel S Quintana, Lars T Westlye, Dag Alnæs, et al.Psychoneuroendocrinology|April 24, 2016
Low dose intranasal oxytocin delivered with Breath Powered device dampens amygdala response to emotional stimuli: A peripheral effect-controlled within-subjects randomized dose-response fMRI trialDaniel S Quintana, Lars T Westlye, Dag Alnæs, et al.Annals of General Psychiatry|January 31, 2007
Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing intervalGeorges M Gharabawi, Natalie C Gearhart, Robert A Lasser, et al.Journal of Clinical Epidemiology|March 19, 2021
Hypothetical case replacement can be used to quantify the robustness of trial resultsKenneth A Frank, Qinyun Lin, Spiro Maroulis, et al.Journal of the American Geriatrics Society|May 31, 2008
Anticholinergic activity of 107 medications commonly used by older adultsMarci L Chew, Benoit H Mulsant, Bruce G Pollock, et al.Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 9, 2006
Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuationMark Hyman Rapaport, Georges M Gharabawi, Carla M Canuso, et al.Pageof 4